Abstract:The goal of HIV therapeutic vaccination is to induce HIV-specific immune response able to control HIV replication. We previously reported that vaccination with <i>ex vivo</i> generated Dendritic Cells (DC) loaded with HIV-lipopeptides in HIV-infected patients (<i>n</i> = 19) on antiretroviral therapy (ART) was well-tolerated and immunogenic. Vaccine-elicited HIV-specific T cell responses were associated with improved control of viral replication following antiretroviral interruption (ATI from w24 to w48). We show an inverse relationship between HIV-specific responses (production of IL-2, IL-13, IL-21, IFN-g, CD4 polyfunctionality, i.e., production of at least two cytokines) and the peak of viral load during ATI. Here we have performed an integrative systems vaccinology analysis including: (i) post vaccination (w16) immune responses assessed by cytometry, cytokine secretion, and Interferon-γ ELISPOT assays; (ii) whole blood and cellular gene expression measured during vaccination; and (iii) viral parameters following ATI, with the objective to disentangle the relationships between these markers and to identify vaccine signatures. During vaccination, 69 gene expression modules out of 260 varied significantly including (by order of significance) modules related to inflammation (Chaussabel Modules M3.2, M4.13, M4.6, M5.7, M7.1, M4.2), plasma cells (M4.11) and T cells (M4.1, 4.15). Cellular immune responses were positively correlated to genes belonging to T cell functional modules (M4.1, M4.15) at w16 and negatively correlated to genes belonging to inflammation modules (M7.1, M5.7, M3.2, M4.13, M4.2). More specifically, we show that prolonged increased abundance of inflammatory gene pathways related to toll-like receptor signaling (especially TLR4) are associated with both lower vaccine immune responses and control of viral replication post ATI. Further comparison of DC vaccine gene signatures with previously reported non-HIV vaccine signatures, such as flu and pneumococcal vaccines, revealed common pathways across vaccines. Overall, these results show that too long duration and too high intensity of vaccine inflammatory responses hamper the magnitude of effector responses.

Optimization and Qualification of a Memory B-cell ELISpot for the Detection of Vaccine-Induced Memory Responses in HIV Vaccine Trials.

High efficiency human memory B cell assay and its application to studying Plasmodium falciparum-specific memory B cells in natural infections.

Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses

Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays

Tissue Memory B Cell Repertoire Analysis after ALVAC/AIDSVAX B/E Gp120 Immunization of Rhesus Macaques.

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Immune-correlates Analysis of an HIV-1 Vaccine Efficacy Trial.

Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients

Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals

Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation

Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus

SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses

Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution

Generation and Characterization of a Bivalent HIV-1 Subtype C Gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

Detection of SARS-CoV-2-Specific Cells Utilizing Whole Proteins and/or Peptides in Human PBMCs Using IFN-ƴ ELISPOT Assay

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses

Preclinical Evaluation of Cellular Immune Responses Elicited by a Polyvalent DNA Prime/protein Boost HIV-1 Vaccine

Divergent Primary Immune Responses Induced by Human Immunodeficiency Virus-1 gp120 and Hepatitis B Surface Antigen Determine Antibody Recall Responses

Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes